Dyne Therapeutics
205 hedge funds and large institutions have $1.29B invested in Dyne Therapeutics in 2025 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 81 increasing their positions, 45 reducing their positions, and 43 closing their positions.
369% more call options, than puts
Call options by funds: $3.39M | Put options by funds: $724K
80% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 45
14% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 43
3% more funds holding
Funds holding: 200 → 205 (+5)
1.83% less ownership
Funds ownership: 109.69% → 107.86% (-1.8%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
51% less capital invested
Capital invested by funds: $2.63B → $1.29B (-$1.34B)
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$47.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$42.5M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
+$42.1M |
| 4 |
JP Morgan Chase
New York
|
+$34.8M |
| 5 |
AC
Armistice Capital
New York
|
+$25.8M |
Top Sellers
| 1 |
Holocene Advisors
New York
|
-$55.3M |
| 2 |
RI
RTW Investments
New York
|
-$50.5M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$45.9M |
| 4 |
JFG
Jefferies Financial Group
New York
|
-$42.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$40.1M |
DYN Hedge Fund Activity: Q1 2025 in Review
205 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2025, worth a combined $1.29B — down 51% from $2.63B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new DYN positions and 43 closed out — a net gain of 6 holders — while 81 added to existing stakes and 45 trimmed.
The largest buyer was RA Capital Management, adding an estimated $47.7M. The largest seller was Holocene Advisors, exiting entirely with an estimated $55.3M sold.
- 205 institutional investors held Dyne Therapeutics (DYN) as of Q1 2025, up from 200 in Q4 2024.
- Funds reported $1.29B of Dyne Therapeutics stock for Q1 2025, down 51% quarter-over-quarter.
- 49 funds opened new Dyne Therapeutics positions in Q1 2025 and 43 closed out, a net change of +6 holders.
- The largest Dyne Therapeutics buyer in Q1 2025 was RA Capital Management, an estimated $47.7M added.
- The largest Dyne Therapeutics seller in Q1 2025 was Holocene Advisors, an estimated $55.3M sold.
Based on aggregated 13F filings for Q1 2025.